Just five months after Novartis put down $310 million for IFM Therapeutics’ inflammation-focused unit, the Big Pharma has come back for more. This time, it is teaming up with IFM Due, the subsidiary ...
Australian investment manager IFM Investors will wind down its domestic private equity unit in coming years, citing a lack of scale to make it commercially viable and a focus on other global ...
Infrastructure powerhouse IFM Investors’ executive pay bill went up by nearly 50 per cent in 2023-24 despite delivering broadly flat revenue and falling profits. The investment giant’s 14 key ...
London | IFM Investors, the asset management giant owned by Australia’s largest superannuation funds, is facing an increasingly hostile reception in Spain amid a boardroom brawl at gas and electricity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback